These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 26838953)
1. Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients. Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Munoz F; Rondi N; Morino M; Racca P; Ricardi U Br J Radiol; 2016; 89(1060):20150832. PubMed ID: 26838953 [TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series. Franco P; Mistrangelo M; Arcadipane F; Munoz F; Sciacero P; Spadi R; Migliaccio F; Angelini V; Bombaci S; Rondi N; Numico G; Ragona R; Cassoni P; Morino M; Racca P; Ricardi U Cancer Invest; 2015 Jul; 33(6):259-66. PubMed ID: 25950188 [TBL] [Abstract][Full Text] [Related]
3. Early-stage Node-negative (T1-T2N0) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U Anticancer Res; 2016 Apr; 36(4):1943-8. PubMed ID: 27069184 [TBL] [Abstract][Full Text] [Related]
4. Locally Advanced (T3-T4 or N+) Anal Cancer Treated with Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy. Franco P; Arcadipane F; Ragona R; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U Anticancer Res; 2016 Apr; 36(4):2027-32. PubMed ID: 27069197 [TBL] [Abstract][Full Text] [Related]
5. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer. Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664 [TBL] [Abstract][Full Text] [Related]
6. Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer. Arcadipane F; Franco P; Ceccarelli M; Furfaro G; Rondi N; Trino E; Martini S; Iorio GC; Mistrangelo M; Cassoni P; Racca P; Morino M; Ricardi U Asia Pac J Clin Oncol; 2018 Jun; 14(3):217-223. PubMed ID: 28856848 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of helical tomotherapy with daily image guidance in anal canal cancer patients. De Bari B; Jumeau R; Bouchaab H; Vallet V; Matzinger O; Troussier I; Mirimanoff RO; Wagner AD; Hanhloser D; Bourhis J; Ozsahin EM Acta Oncol; 2016 Jun; 55(6):767-73. PubMed ID: 27034083 [TBL] [Abstract][Full Text] [Related]
8. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer. Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814 [TBL] [Abstract][Full Text] [Related]
9. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071 [TBL] [Abstract][Full Text] [Related]
10. French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients. Vendrely V; Henriques de Figueiredo B; Rio E; Benech J; Belhomme S; Lisbona A; Frison E; Doussau A; Nomikossoff N; Mahé MA; Kantor G; Maire JP Radiat Oncol; 2015 Aug; 10():170. PubMed ID: 26268888 [TBL] [Abstract][Full Text] [Related]
11. PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. Zimmermann M; Beer J; Bodis S; von Moos R; Vlachopoulou V; Zwahlen DR; Oehler C Acta Oncol; 2017 Dec; 56(12):1734-1740. PubMed ID: 28557585 [TBL] [Abstract][Full Text] [Related]
12. Volumetric intensity-modulated arc therapy vs. 3-dimensional conformal radiotherapy for primary chemoradiotherapy of anal carcinoma: Effects on treatment-related side effects and survival. Weber HE; Dröge LH; Hennies S; Herrmann MK; Gaedcke J; Wolff HA Strahlenther Onkol; 2015 Nov; 191(11):827-34. PubMed ID: 26050046 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of definitive radiation with volumetric modulated arc therapy and concurrent chemotherapy for squamous cell carcinoma of the anus in a regional Australian cancer centre. Hsieh MT; Shakespeare TP; Winkley L; Goonetilleke D; Yap SZL; Tahir ARM J Med Imaging Radiat Oncol; 2024 Apr; 68(3):325-332. PubMed ID: 38450897 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience. Khosla D; Kapoor R; Dey T; Kataria V; Singh R; Kumar D; Oinam AS; Gupta R; Rana SS; Shah J; Singh H; Irrinki S; Madan R J Gastrointest Cancer; 2024 Jun; 55(2):759-767. PubMed ID: 38236375 [TBL] [Abstract][Full Text] [Related]
15. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of patients with anal cancer treated with volumetric-modulated arc therapy or intensity-modulated radiotherapy and concurrent chemotherapy. Yucel S; Kadioglu H; Gural Z; Akgun Z; Saglam EK J Cancer Res Ther; 2021; 17(1):51-55. PubMed ID: 33723132 [TBL] [Abstract][Full Text] [Related]